Nr 546 with rationale - Study guides, Class notes & Summaries

NR 546 ACTUAL MIDTERM EXAM/ NR546 WEEK 3 ACTUAL EXAM QUESTIONS AND COMPLETE 100% CORRECT ANSWERS 2024 WITH RATIONALES VERIFIED BY EXPERTS AND WELL EXPLAINED GRADED A+ LATEST UPDATE 2024 ALREADY PASSED!!!!!! WWITH 100% GUARANTEED SUCCESS AFTER DOWNLOAD ( ALL YOU NEED TO PASS YOUR EXAMS) A 44-year-old woman with schizophrenia has developed tardive dyskinesia after taking haloperidol 15 mg/day for 2 years. Which of the following would be the most appropriate pharmacologic mechanism to manage her...

Drug Name Indication Neurotransmitter(s) Affected Target Symptoms Half-life (T1/2), Metabolism (CYP 450 enzyme) Notable Side Effects (link to NT or affected brain circuit) Initial Dosing Considerations Specific lifespan considerations (age, pregnancy, breastfeeding) Buprenorphine (Subutex) Indication: • Maintenance treatment of opioid dependence • Maintenance treatment of opioid dependence in patients who have achieved and sustainced Half-life: 24-42 hours CYP450: ...

NR 546 Midterm Exam 2023/2024 Questions AND Answers Update A+ What should the PMHNP consider when prescribing chemical restraints? - Answer-- allergy status -prior med hx for adverse drug reactions r/t the meds ordered in the chemical restraint -state regulations regarding chemical restrains must be reviewed Are the PMHNP and other staff liable if the client has an allergic reaction or adverse side effects to the drugs used for chemical restraint? - Answer-No. The client has been court-...

NR 546 Week 6 Addiction Medication Table QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A+ Drug Name Indication Neurotransmitter(s) Affected Target Symptoms Half-life (T1/2), Metabolism (CYP 450 enzyme) Notable Side Effects (link to NT or affected brain circuit) Initial Dosing Considerations Specific lifespan considerations (age, pregnancy, breastfeeding) Buprenorphine (Subutex) Indication: • Maintenance treatment of opioid dep...

NR 546 Week 8 Course Reflection QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A+

NR 546 Week 3 Discussion: Schizophrenia 1. Selectone drugtotreatthe diagnosis(es)orsymptoms. 2. Listmedicationclassandmechanismofactionforthechosenmedication. 3. Writetheprescriptioninprescriptionformat. 4. Provide an evidence-based rationale for the selected medication 5. List any side effects or adverse effects associated with the medication. 6. Include any required diagnostic testing. State the time frame for this testing (testing is before medication initiation or q 3 month...

NR 546 Week 6 Addiction Medication Table QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A+ Drug Name Indication Neurotransmitter(s) Affected Target Symptoms Half-life (T1/2), Metabolism (CYP 450 enzyme) Notable Side Effects (link to NT or affected brain circuit) Initial Dosing Considerations Specific lifespan considerations (age, pregnancy, breastfeeding) Buprenorphine (Subutex) Indication: • Maintenance treatment of opioid dependence ...

NR 546 Week 8 Course Reflection QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A+ 2 Over the course of the last 8 weeks, I was able to incrementally improve on core competencies that the AGNP program has set to achieve by completion of course and clinical criteria. The care provided in clinical situations adhered to the three core categories: MSN Program Outcome, MSN Essential, and Nurse Practitioner Core Competency. Within these categories one specif...

NR 546 Week 6 Addiction Medication Table QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A+

NR 546 Week 6 Addiction Medication Table QUESTIONS AND CORRECT DETAILED ANSWERS WITH RATIONALES (VERIFIED ANSWERS) |ALREADY GRADED A